高尔基体蛋白73诊断原发性肝癌的临床评价

Clinical evaluation of Golgi protein 73 in the Diagnosis of Primary Hepatic Cancer

目的评价新的肿瘤标志物高尔基体蛋白73(GP73)对原发性肝癌的临床诊断价值。方法用ELIAS法对40例原发性肝癌患者(肝癌组)、40例慢性肝病患者(肝病组)与40名健康体检者(对照组)血清标本进行GP73测定,然后对结果进行统计学分析,并与病理结果("金标准")比较,分析灵敏度、特异性和符合率。结果①肝癌组血清GP73水平(中位数:299.4)明显高于肝病组(中位数:83.4)和对照组(中位数:53.2),差异具有统计学意义(P均<0.01);②与"金标准"病理结果比较,敏感度为90.0%、特异性为70.0%和符合率为76.7%。结论 GP73是诊断原发性肝癌较为敏感的肿瘤标志物,其敏感性高于AFP,具有广泛的临床应用价值。

Objective To evaluate the clinical diagnostic value of new tumor marker Golgi protein 73 （GP73） in the Diagnosis of Primary Hepatic Cancer. Methods The levels of serum GP73 in 40 cases with PHC,40 cases with chronic hepatitis and 40 healthy persons were detected by Enzyme-linked Immunosorbent Assay（ELISA）, their results of serum GP73 were statistically analyzed and compared with pathology（as Gold standard）, their sensibility, specificity and ac- cordance rate were analyzed. Results ①The level of serum GP73 in patients with PHC was significantly higher than that of chronic disease of the liver and healthy persons（median were 299.4.83.4.53.2） ,the difference was statistically significant（P〈0.05） ; ②Compared with pathology （as Gold standard）, their sensibility, specificity and accordance rate were 90.0 %, 70.0% and 76.7 %. Conclusion GP73 was considered to be better sensitive tumor marker in the Diagnosis of Primary Hepatic Cancer than AFP,it had widespread clinical practical value.